サンプル依頼リスト カート
  • English
  • Korean
表紙：慢性骨髄性白血病治療の世界市場レポート 2024年
市場調査レポート
商品コード
1415662

慢性骨髄性白血病治療の世界市場レポート 2024年

Chronic Myeloid Leukemia Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
慢性骨髄性白血病治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

慢性骨髄性白血病治療市場規模は近年力強く成長しています。2023年の85億8,000万米ドルから2024年には92億米ドルへとCAGR7.2％で拡大します。実績期間の成長は、慢性骨髄性白血病の有病率の上昇、がん治療に対する意識の高まり、政府の取り組み、慢性骨髄性白血病治療の研究開発活動の高まりに起因しています。

慢性骨髄性白血病治療市場規模は、今後数年間で力強い成長が見込まれます。2028年には年間平均成長率（CAGR）7.0％で120億6,000万米ドルに成長します。予測期間の成長は、より効果的で忍容性の高い治療に対する需要の高まり、ヘルスケア支出の増加、慢性骨髄性白血病治療への投資、個別化医療の成長に起因すると考えられます。予測期間の主な動向には、診断とスクリーニングの改善、慢性骨髄性白血病の革新的治療、標的療法の開発、高度な早期診断とスクリーニング、モニタリング技術などが含まれます。

骨髄性白血病の罹患率の上昇は、今後数年間における慢性骨髄性白血病（CML）治療市場の拡大を牽引する構えです。骨髄性白血病は骨髄に発生するがんの一種で、様々な種類の血液細胞を産生する細胞を侵します。慢性骨髄性白血病（CML）治療の主な目的は、白血病の根本原因に対処することで骨髄機能を強化し、最終的には血球数の低下に関連する合併症のリスクを低下させ、化学療法や移植の必要性を減らし、骨髄性白血病患者の生存率を改善することです。例えば、2023年1月、米国の任意団体である米国がん協会は、2023年中に成人の急性骨髄性白血病（AML）の患者数は約20,380人、死亡者数は約11,310人と推定しています。その結果、骨髄性白血病の発生率の上昇が慢性骨髄性白血病（CML）治療市場の成長の原動力となっています。

染色体異常の発生率の上昇は、今後数年間における慢性骨髄性白血病（CML）治療市場拡大の主要な促進要因になると予想されます。染色体異常は、遺伝情報の重要な担い手である個人の染色体における構造的または数値的な異常を包含しており、患者の予後に重大な影響を及ぼし、特にCMLの場合、より積極的な治療が必要となる可能性があります。例えば、サウジアラビアで実施された調査によると、先天異常のある新生児59人のうち39.3％に染色体異常が認められ、新生児集中治療室（NICU）入室者全体の2.3％を占めていたことが、米国を拠点とする生物医学情報学と計算健康データ科学研究の専門機関である国立医学図書館（NLM）の報告から明らかになった。その結果、染色体異常の有病率の増加が慢性骨髄性白血病（CML）治療市場の拡大を牽引しています。

2023年の慢性骨髄性白血病治療市場で最大の地域は北米でした。慢性骨髄性白血病治療レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の慢性骨髄性白血病治療市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 標的療法
  • 化学療法
  • 放射線治療
  • 脾臓摘出術
  • 幹細胞移植
  • 世界の慢性骨髄性白血病治療市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • その他
  • 世界の慢性骨髄性白血病治療市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • その他

第7章 地域および国の分析

  • 世界の慢性骨髄性白血病治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の慢性骨髄性白血病治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 慢性骨髄性白血病治療市場の競合情勢
  • 慢性骨髄性白血病治療市場の企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson Limited
    • F. Hoffmann-La Roche AG
    • AbbVie Inc.
    • Novartis AG

第31章 その他の主要および革新的な企業

  • Merck and Co. Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AstraZeneca Plc
  • GSK Plc
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc
  • Otsuka Holdings Co Ltd.
  • Mylan N.V.
  • Astellas Pharma Inc.
  • Incyte Corporation
  • Lupin Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12261

“Chronic Myeloid Leukemia Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic myeloid leukemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic myeloid leukemia treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The chronic myeloid leukemia treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Targeted Therapy; Chemotherapy; Radiation Therapy; Splenectomy; Stem Cell Transplant
  • 2) By Route of Administration: Oral; Parenteral; Other Route of Administrations
  • 3) By End-User: Hospitals; Specialty Clinics; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; F. Hoffmann-La Roche AG; AbbVie Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Chronic myeloid leukemia (CML) constitutes a form of cancer that exerts its impact on the bone marrow and blood cells. It is characterized by the excessive production of abnormal white blood cells, referred to as granulocytes. The core objective of CML treatment is the management of the disease, alleviation of symptoms, and enhancement of the overall quality of life for patients grappling with this condition.

Treatment options in the domain of chronic myeloid leukemia encompass a range of approaches, including targeted therapy, chemotherapy, radiation therapy, splenectomy, and stem cell transplantation. Among these, targeted therapy assumes prominence as a cancer treatment modality focused on specific molecules or pathways integral to the growth and survival of cancer cells. The administration of these treatments can occur through diverse routes, including oral and parenteral methods, and caters to various end-users such as hospitals and specialized clinics, ultimately underscoring the comprehensive nature of CML management.

The chronic myeloid leukemia treatment market research report is one of a series of new reports from The Business Research Company that provides chronic myeloid leukemia treatment market statistics, including chronic myeloid leukemia treatment industry global market size, regional shares, competitors with a chronic myeloid leukemia treatment market share, detailed chronic myeloid leukemia treatment market segments, market trends and opportunities and any further data you may need to thrive in the chronic myeloid leukemia treatment industry. This chronic myeloid leukemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic myeloid leukemia treatment market size has grown strongly in recent years. It will grow from $8.58 billion in 2023 to $9.2 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising prevalence of chronic myeloid leukemia, growing awareness about cancer treatment, government initiatives, growing research and development activities for chronic myeloid leukemia treatments.

The chronic myeloid leukemia treatment market size is expected to see strong growth in the next few years. It will grow to $12.06 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing demand for effective and more tolerable treatments, rising healthcare spending, investments in chronic myeloid leukemia treatments, growing personalized medicine. Major trends in the forecast period include improved diagnosis and screening, innovative treatments for chronic myeloid leukemia, development of targeted therapies, advanced early diagnosis and screening, monitoring technologies.

The rising incidence of myeloid leukemia is poised to drive the expansion of the chronic myeloid leukemia (CML) treatment market in the coming years. Myeloid leukemia, a form of cancer originating in the bone marrow, affects the cells responsible for producing various blood cell types. The primary objective of chronic myeloid leukemia (CML) treatment is to enhance bone marrow function by addressing the root cause of leukemia, ultimately lowering the risk of complications related to low blood cell counts, reducing the necessity for chemotherapy and transplants, and improving survival rates among individuals with myeloid leukemia. For instance, in January 2023, the American Cancer Society, a US-based voluntary health organization, estimated that there were approximately 20,380 cases and 11,310 deaths from acute myeloid leukemia (AML) in adults during the year 2023. Consequently, the escalating incidence of myeloid leukemia serves as a driving force behind the chronic myeloid leukemia (CML) treatment market's growth.

The rising incidence of chromosome abnormalities is expected to be a key driver behind the expansion of the chronic myeloid leukemia (CML) treatment market in the coming years. Chromosome abnormalities, which encompass structural or numerical irregularities in an individual's chromosomes-critical carriers of genetic information, have a significant impact on patients' prognoses and may necessitate more aggressive treatments, particularly in cases of CML. For instance, based on a study conducted in Saudi Arabia, it was revealed that chromosome abnormalities were present in 39.3% of 59 newborn infants with congenital anomalies, accounting for 2.3% of total neonatal intensive care unit (NICU) admissions, as reported by the National Library of Medicine (NLM), a US-based institution specializing in biomedical informatics and computational health data science research. Consequently, the increasing prevalence of chromosome abnormalities is driving the expansion of the chronic myeloid leukemia (CML) treatment market.

The growth of the chronic myeloid leukemia treatment market is hampered by the significant costs associated with treatment during the forecast period. The elevated expenses related to chronic myeloid leukemia (CML) treatments present a substantial barrier for patients, leading to various adverse consequences. These consequences encompass reduced treatment demand, delayed diagnosis and intervention, financial hardships for patients, increased healthcare outlays, limited accessibility to essential therapies, and an overall diminished quality of life. For instance, as reported by the National Library of Medicine in December 2022, the total care provider cost for treating chronic myeloid leukemia (CML) was $23,014.40 for imatinib and $43,442.69 for nilotinib. Thus, the high treatment costs are impeding the growth of the chronic myeloid leukemia treatment market.

Prominent companies in the chronic myeloid leukemia (CML) treatment market prioritize the development of groundbreaking diagnostic products to maintain their market presence. An illustrative instance of such innovation is found in the actions of Precipio, Inc., a US-based diagnostic company specializing in cancer diagnostics. For instance, in August 2023, Precipio, Inc. introduced the BCR-ABL 2.0 Panel, specifically designed for chronic myeloid leukemia (CML) diagnosis. This advanced panel plays a pivotal role in identifying the BCR-ABL1 gene, which is crucial for diagnosing CML. It stands out as the most sophisticated BCR-ABL panel, distinguished by its comprehensive coverage, streamlined workflow, reduced costs, and the enhanced quality of patient care. Notably, it includes the detection of ABL1 mutations, eliminating the necessity for a secondary round of testing for the BCR-ABL1 gene and providing highly accurate results. This remarkable innovation significantly shapes the landscape of chronic myeloid leukemia (CML) treatment.

In November 2021, Pfizer Inc., a renowned US-based pharmaceutical and biotechnology firm renowned for producing various medications for chronic myeloid leukemia (CML), successfully acquired Trillium Therapeutics Inc. for a significant sum of $2.2 billion. This strategic acquisition by Pfizer is driven by its commitment to expanding and enhancing its oncology portfolio. The newly acquired biologics from Trillium Therapeutics are specifically engineered to empower a patient's innate immune system, enabling it to more effectively identify and eliminate cancer cells. Trillium Therapeutics Inc., on the other hand, is a clinical-stage immuno-oncology company headquartered in Canada, and it is dedicated to advancing therapies tailored for the treatment of chronic myeloid leukemia (CML). This collaboration stands to greatly bolster Pfizer's position in the field of oncology.

Major players in the chronic myeloid leukemia treatment market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Otsuka Holdings Co Ltd., Mylan N.V., Astellas Pharma Inc., Incyte Corporation, Lupin Limited, Seattle Genetics Inc., Innovent Biologics Inc., Xencor Inc., ARIAD Pharmaceuticals Inc., Celon Laboratories Pvt. Ltd.

North America was the largest region in the chronic myeloid leukemia treatment market in 2023. The regions covered in chronic myeloid leukemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic myeloid leukemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic myeloid leukemia treatment market consists of revenues earned by entities by providing diagnosis and staging, medical consultations and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic myeloid leukemia (CML) market also includes sales of imatinib, dasatinib, bosutinib and ponatinib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Chronic Myeloid Leukemia Treatment Market Characteristics

3. Chronic Myeloid Leukemia Treatment Market Trends And Strategies

4. Chronic Myeloid Leukemia Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Chronic Myeloid Leukemia Treatment Market Size and Growth

  • 5.1. Global Chronic Myeloid Leukemia Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Chronic Myeloid Leukemia Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Chronic Myeloid Leukemia Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Chronic Myeloid Leukemia Treatment Market Segmentation

  • 6.1. Global Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy
  • Splenectomy
  • Stem Cell Transplant
  • 6.2. Global Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • Other Route of Administrations
  • 6.3. Global Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Speciality Clinics
  • Other End-Users

7. Chronic Myeloid Leukemia Treatment Market Regional And Country Analysis

  • 7.1. Global Chronic Myeloid Leukemia Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Chronic Myeloid Leukemia Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Chronic Myeloid Leukemia Treatment Market

  • 8.1. Asia-Pacific Chronic Myeloid Leukemia Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Chronic Myeloid Leukemia Treatment Market

  • 9.1. China Chronic Myeloid Leukemia Treatment Market Overview
  • 9.2. China Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Chronic Myeloid Leukemia Treatment Market

  • 10.1. India Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Chronic Myeloid Leukemia Treatment Market

  • 11.1. Japan Chronic Myeloid Leukemia Treatment Market Overview
  • 11.2. Japan Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Chronic Myeloid Leukemia Treatment Market

  • 12.1. Australia Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Chronic Myeloid Leukemia Treatment Market

  • 13.1. Indonesia Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Chronic Myeloid Leukemia Treatment Market

  • 14.1. South Korea Chronic Myeloid Leukemia Treatment Market Overview
  • 14.2. South Korea Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Chronic Myeloid Leukemia Treatment Market

  • 15.1. Western Europe Chronic Myeloid Leukemia Treatment Market Overview
  • 15.2. Western Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Chronic Myeloid Leukemia Treatment Market

  • 16.1. UK Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Chronic Myeloid Leukemia Treatment Market

  • 17.1. Germany Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Chronic Myeloid Leukemia Treatment Market

  • 18.1. France Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Chronic Myeloid Leukemia Treatment Market

  • 19.1. Italy Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Chronic Myeloid Leukemia Treatment Market

  • 20.1. Spain Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Chronic Myeloid Leukemia Treatment Market

  • 21.1. Eastern Europe Chronic Myeloid Leukemia Treatment Market Overview
  • 21.2. Eastern Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Chronic Myeloid Leukemia Treatment Market

  • 22.1. Russia Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Chronic Myeloid Leukemia Treatment Market

  • 23.1. North America Chronic Myeloid Leukemia Treatment Market Overview
  • 23.2. North America Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Chronic Myeloid Leukemia Treatment Market

  • 24.1. USA Chronic Myeloid Leukemia Treatment Market Overview
  • 24.2. USA Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Chronic Myeloid Leukemia Treatment Market

  • 25.1. Canada Chronic Myeloid Leukemia Treatment Market Overview
  • 25.2. Canada Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Chronic Myeloid Leukemia Treatment Market

  • 26.1. South America Chronic Myeloid Leukemia Treatment Market Overview
  • 26.2. South America Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Chronic Myeloid Leukemia Treatment Market

  • 27.1. Brazil Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Chronic Myeloid Leukemia Treatment Market

  • 28.1. Middle East Chronic Myeloid Leukemia Treatment Market Overview
  • 28.2. Middle East Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Chronic Myeloid Leukemia Treatment Market

  • 29.1. Africa Chronic Myeloid Leukemia Treatment Market Overview
  • 29.2. Africa Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration , Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Chronic Myeloid Leukemia Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Chronic Myeloid Leukemia Treatment Market Competitive Landscape
  • 30.2. Chronic Myeloid Leukemia Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson Limited
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. F. Hoffmann-La Roche AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Chronic Myeloid Leukemia Treatment Market Other Major And Innovative Companies

  • 31.1. Merck and Co. Inc.
  • 31.2. Sanofi S.A.
  • 31.3. Bristol-Myers Squibb Company
  • 31.4. AstraZeneca Plc
  • 31.5. GSK Plc
  • 31.6. Takeda Pharmaceutical Company Limited
  • 31.7. Amgen Inc.
  • 31.8. Boehringer Ingelheim International GmbH
  • 31.9. Teva Pharmaceutical Industries Ltd.
  • 31.10. Astellas Pharma Inc
  • 31.11. Otsuka Holdings Co Ltd.
  • 31.12. Mylan N.V.
  • 31.13. Astellas Pharma Inc.
  • 31.14. Incyte Corporation
  • 31.15. Lupin Limited

32. Global Chronic Myeloid Leukemia Treatment Market Competitive Benchmarking

33. Global Chronic Myeloid Leukemia Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Chronic Myeloid Leukemia Treatment Market

35. Chronic Myeloid Leukemia Treatment Market Future Outlook and Potential Analysis

  • 35.1 Chronic Myeloid Leukemia Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Chronic Myeloid Leukemia Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Chronic Myeloid Leukemia Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer